<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085823</url>
  </required_header>
  <id_info>
    <org_study_id>fbf001</org_study_id>
    <nct_id>NCT03085823</nct_id>
  </id_info>
  <brief_title>The All-comers Sirolimus-coated Balloon European Registry</brief_title>
  <acronym>EASTBOURNE</acronym>
  <official_title>The All-comers Sirolimus-coated Balloon European Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatebenefratelli and Ophthalmic Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fatebenefratelli and Ophthalmic Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the performance of a Sirolimus-eluting
      Drug Coated Balloon for the treatment of any type of coronary lesions, including native
      vessel disease and in stent restenosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic success</measure>
    <time_frame>10 minutes after percutaneous transluminal coronary angioplasty</time_frame>
    <description>residual stenosis &lt;50%, TIMI FLOW 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural success</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>angiographic success in absence of in-hospital events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events (cardiac death, Acute myocardial infarction, target lesion revascularization)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>very single component of major adverse cardiac events (cardiac death, Acute myocardial infarction, target lesion revascularization)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Angioplasty, Balloon, Coronary</condition>
  <condition>Coronary Angioplasty, Transluminal Balloon</condition>
  <condition>Arteriosclerosis, Coronary</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Coated Balloon</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a clinical indication for PCI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at least 18

          -  patients with symptomatic coronary artery disease (including chronic stable angina,
             silent ischemia, acute coronary syndromes) with clinical indication to percutaneous
             coronary intervention.

        Exclusion Criteria:

          -  patients with one or more of the following criteria: known (and untreatable)
             hypersensitivity or contraindication to Aspirin, Heparin, Clopidogrel, Prasugrel,
             Ticagrelor, Sirolimus, or a sensitivity to contrast media which cannot be adequately
             pre-medicated.

          -  patients enrolled in another trial.

        Target lesion/vessel with any of the following characteristics:

          -  successful pre-dilatation not performed in the target lesion, or not efficacious
             (residual stenosis &gt;50%);

          -  severe calcification of the target vessel, also proximal to the lesion;

          -  highly tortuous lesions which can impair access of device to treatment site.

          -  visible thrombus at lesion which is not treatable with aspiration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernardo Cortese, MD</last_name>
    <email>bcortese@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unita' Operativa di Cardiologia</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardo Cortese, MD</last_name>
      <email>bcortese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bernardo Cortese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fatebenefratelli and Ophthalmic Hospital</investigator_affiliation>
    <investigator_full_name>Bernardo Cortese</investigator_full_name>
    <investigator_title>MD FESC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

